- Dr. Brian A. Van Tine
- Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO, USA.
Website | E-mail
Special Issue Introduction
Soft Tissue Sarcoma, GIST and Bone Sarcomas are a diverse group of over 150 subtypes of mesenchymal tumors. The diversity of therapeutics utilized by the sarcoma specialist makes this a very complex area. As a result, we call for reviews in the area of "Advanced Research of Drug Resistance in Soft Tissue and Bone Sarcomas". While there is a fundamental understanding of GIST, the additional new lines of therapy are making our understanding of mechanisms of resistance an evolving area. Additionally, there is some understanding of mechanisms contributing to treatment failure of chemotherapy agents in soft tissue sarcoma and bone tumors. With a number of new agents being tested in the sarcoma space, a review of mechanisms of resistance to these agents is warranted, as this will allow for the design of better clinical trials. For example, little is known about resistance to SPHERE-T and ADCs. In addition, the classic agents, such as doxorubicin, ifosfamide, gemcitabine, etc. also need a comprehensive review of their mechanisms and mechanisms of resistance, especially within multi-agent combinations. Finally, our understanding of the resistance to immunotherapies has hindered clinical development. Therefore, this review should be timely and provide a background and compass for further advances in the treatment of all types of sarcoma.
Submission Deadline31 May 2021